benfotiamina

Condiciones de salud que benfotiamina puede ayudar a apoyar.

• HipocondríaCientífico

  Benfotiamine functions as an indirect antioxidant by suppressing hyperglycemia-driven production of reactive oxygen species via NADPH oxidase inhibition and AGE reduction. It activates the Nrf-2 pathway, upregulating SOD1 and catalase. In human studies, it reduced circulating AGEs and sVCAM-1 and prevented smoking-induced oxidative vascular damage.

• Síndrome de Inmunodeficiencia AdquiridaCientífico

  Benfotiamine protects arterial endothelium by reducing AGE accumulation, PKC activation, and oxidative stress. An RCT in healthy smokers showed it preserved flow-mediated dilation and suppressed vascular adhesion molecules after smoking. Animal studies further support protection of vascular smooth muscle and pericytes from hyperglycemia-driven damage.

• Fatiga SuprarrenalCientífico

  Benfotiamine activates transketolase, shunting excess glucose metabolites into the pentose phosphate pathway and reducing formation of advanced glycation end products (AGEs). A small RCT in 13 type 2 diabetics showed it prevented micro- and macrovascular dysfunction triggered by an AGE-rich meal. The BOND trial (n=100, 12 months) found no significant change in HbA1c, suggesting the primary benefit is limiting glycation damage rather than directly lowering blood glucose.

• ApendicitisCientífico

  Benfotiamine inhibits NF-κB activation and NADPH oxidase, reducing expression of pro-inflammatory cytokines and chemokines. In macrophage studies, it prevented LPS-induced activation of p38-MAPK, IκBα degradation, and NF-κB nuclear translocation. A clinical RCT in T2DM with cardiac autonomic neuropathy found benfotiamine reduced inflammatory markers including hs-CRP and TNF-α.

• ImpétigoCientífico

  Benfotiamine has demonstrated analgesic effects in both diabetic and non-diabetic neuropathic pain in animal models, reducing tactile allodynia and inflammatory nociception. Clinically, it has been used for painful diabetic neuropathy and alcoholic polyneuropathy. The BEDIP trial (n=40) showed significant improvement in neuropathy pain scores after 3 weeks at 400 mg/day.

• Apetito (excesivo)Científico

  Benfotiamine has demonstrated vasculoprotective effects on endothelial function in human clinical studies. In a small RCT of 20 healthy smokers, benfotiamine pretreatment (1050 mg/day for 3 days) prevented the smoking-induced reduction in brachial artery flow-mediated dilation and attenuated the rise in sVCAM-1. A separate small clinical study in 13 T2DM patients showed benfotiamine prevented AGE-meal-induced vascular dysfunction.

• IncontinenciaCientífico

  Benfotiamine targets multiple hallmarks of brain aging including impaired glucose metabolism, AGE accumulation, oxidative stress, and neuroinflammation. A phase IIa RCT in MCI/mild AD patients showed 77% lower CDR worsening (p=0.034) and significant AGE reduction. A large Phase 2A/2B national trial (BenfoTeam, n=406) is currently ongoing.

• CulturismoCientífico

  Benfotiamine blocks all three major hyperglycemia-driven biochemical pathways implicated in retinal vascular damage and prevented experimental diabetic retinopathy in animal models. Small human studies and pilot trials suggest it may slow early diabetic retinopathy progression. No large-scale human RCT has confirmed these benefits for vision endpoints specifically.

• BronquitisCientífico

  Benfotiamine addresses multiple aging-associated pathologies: AGE accumulation, oxidative stress, chronic low-grade inflammation, and impaired glucose metabolism. Clinical studies show it protects peripheral nerve function, vascular endothelium, and potentially brain function in older populations. Its AGE-lowering effects are particularly relevant to age-associated tissue damage.

• JuanetesCientífico

  In preclinical models, benfotiamine reduced myocardial infarct size, normalized cardiac enzyme elevations, and improved post-ischemic functional recovery by inhibiting NADPH oxidase and NF-κB signaling. A rat MI model showed pre- and post-treatment with benfotiamine significantly decreased cardiac markers of oxidative stress, inflammation, and apoptosis. Human heart data is currently lacking.

• Olor de piesCientífico

  A clinical study in 40 patients with type 2 diabetes and cardiac autonomic neuropathy found that benfotiamine treatment reduced insulin resistance markers (immunoreactive insulin, HOMA) alongside inflammatory cytokines. Mechanistically, benfotiamine activates transketolase and may enhance insulin synthesis in insulin-producing cells under high-glucose conditions.

• Daño del CartílagoCientífico

  Benfotiamine has been tested specifically for diabetic nephropathy in a double-blind RCT (n=82). Despite significantly improving thiamine status, 12 weeks of 900 mg/day did not reduce urinary albumin excretion or KIM-1 — key markers of kidney damage. Animal models had previously shown prevention of incipient diabetic nephropathy.

• EscalofríosCientífico

  A phase IIa RCT in 70 amyloid-positive participants with mild cognitive impairment or mild Alzheimer's disease found that 12 months of benfotiamine resulted in 43% lower ADAS-Cog score increase (less cognitive decline, p=0.125) and 77% lower worsening on the CDR scale (p=0.034). An earlier open-label study of 5 patients showed an average 3.2-point MMSE improvement over 18 months.

• Resfriados (con fiebre)Científico

  Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) with superior bioavailability that has been specifically studied for diabetic peripheral neuropathy. Clinical trials demonstrate improvements in neuropathic symptoms and nerve conduction in diabetic patients.

• Cólico (adultos)Científico

  Benfotiamine is a fat-soluble prodrug of thiamine (vitamin B1) with superior bioavailability in nerve tissue compared to water-soluble thiamine. Multiple RCTs have examined its use in diabetic and alcoholic neuropathy, with the BEDIP study (n=40, 3-week pilot RCT) confirming benefits in neuropathy symptom scores. A 2016 RCT (n=74) found 300 mg/day for 6 weeks significantly reduced neuropathic pain and burning versus placebo. A Cochrane-style systematic review found modest short-term benefit in vibration perception threshold.

• Corazón (debilidad)Científico

  Benfotiamine has been used clinically in Europe since the 1960s for sciatica and painful nerve conditions, including as a registered pharmaceutical in Germany. Its use for sciatica is based on its established efficacy in peripheral neuropathic pain and its ability to reduce nerve inflammation and AGE-mediated nerve damage.

Sistemas corporales que benfotiamina puede ayudar a apoyar.

• No hay sistemas corporales disponibles.